Gyms could provide vital to support governments and the healthcare systems to tackle obesity / shutterstock_Amorn Suriyan
Trade associations from around the world have joined forces to lobby governments and health systems on the importance of prescribing lifestyle interventions, including physical activity and nutrition, alongside GLP-1 medications.
The World Obesity Federation, UK Active, the Health and Fitness Association, AUSactive, Exercise New Zealand and Fitness Industry Council of Canada have worked together to outline a global framework for integrating prevention, treatment and long-term health outcomes.
The message of the statement is that obesity medications are not a standalone solution and reliance on medication alone may lead to poor long-term outcomes, including loss of muscle mass, diminished functional capacity and widening health inequalities.
Richard Beddie, CEO of Exercise New Zealand, said although GLP-1 therapies can be a significant tool in addressing obesity if they’re not paired with strength training and other lifestyle changes, “the result will be increased long-term health costs for the health system and worse health outcomes for individuals.”
The organisations call for a wraparound approach that combines pharmacological treatment with sustained investment in physical activity, nutrition and supportive environments. The organisations have also committed to advancing evidence-based, integrated approaches that combine medication with physical activity and nutrition support.
“Medication is only one piece of the puzzle,” said Zach Weston, executive director of the Fitness Industry Council of Canada. “For these therapies to deliver true, sustainable health outcomes, they must be anchored by the professional guidance and supportive environments found in our fitness centres.
“Our facilities are more than just places to exercise; they are essential community hubs for maintaining the muscle mass and functional capacity that are often at risk during rapid weight loss.
“By integrating fitness infrastructure into the global rollout of these medications, we ensure that patients aren’t just losing weight but are gaining the strength and long-term vitality necessary for a healthier life.”
Almost three billion adults worldwide are overweight or living with obesity and the figure is projected to rise to four billion by 2035.
The World Health Organization (WHO), which collaborates with The World Obesity Federation, published its policy on GLP-1s in December 2025.
